^
CANCER:

Genito-urinary Cancer

PBRM1 mutation
Clear Cell Renal Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
Eur Urol - 1 week
No biomarker
Urothelial Cancer
enfortumab vedotin
Sensitive: A1 - Approval
Seagen Press Release - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
sunitinib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
pazopanib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
RCC
pembrolizumab
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
tivozanib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
MET amplification
RCC
savolitinib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Prostate Cancer
olaparib
Sensitive: B - Late Trials
Merck (MSD) Press Release - 3 weeks
FGFR1 mutation
Urothelial Cancer
TAS 120
Sensitive: C3 – Early Trials
Cancer Discov - 3 weeks
No biomarker
RCC
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
apalutamide
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
avelumab
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
PD-L1 expression
RCC
avelumab + axitinib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
histrelin acetate
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
cabazitaxel
Sensitive: A1 - Approval
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
RCC
avelumab + axitinib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
enzalutamide
Sensitive: A1 - Approval
No biomarker
RCC
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
RCC
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
relugolix
Sensitive: A1 - Approval
No biomarker
Germ Cell Tumors
dactinomycin
Sensitive: A1 - Approval
No biomarker
Testicular Cancer
etoposide IV
Sensitive: A1 - Approval
No biomarker
Testicular Cancer
cisplatin
Sensitive: A1 - Approval
No biomarker
Testicular Cancer
ifosfamide
Sensitive: A1 - Approval
No biomarker
RCC
sorafenib
Sensitive: A1 - Approval
No biomarker
RCC
tivozanib
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
mitomycin urothelial gel
Sensitive: A1 - Approval
No biomarker
RCC
temsirolimus
Sensitive: A1 - Approval
No biomarker
RCC
sunitinib
Sensitive: A1 - Approval
No biomarker
RCC
everolimus + lenvatinib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
docetaxel + prednisone
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
abiraterone acetate
Sensitive: A1 - Approval
No biomarker
RCC
everolimus
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
degarelix
Sensitive: A1 - Approval
PD-L1 expression
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
RCC
bevacizumab + pegylated interferon α -2a
Sensitive: A1 - Approval
ATM mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
darolutamide
Sensitive: A1 - Approval
No biomarker
RCC
cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
Bladder Cancer
cisplatin
Sensitive: A1 - Approval
No biomarker
RCC
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
No biomarker
Germ Cell Tumors
ifosfamide
Sensitive: A1 - Approval
No biomarker
RCC
pembrolizumab + axitinib
Sensitive: A1 - Approval
No biomarker
RCC
nivolumab
Sensitive: A1 - Approval
FGFR2 mutation
Urothelial Cancer
erdafitinib
Sensitive: A1 - Approval
No biomarker
RCC
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
Sensitive: A1 - Approval
No biomarker
RCC
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
RCC
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
FGFR3 mutation
Urothelial Cancer
erdafitinib
Sensitive: A1 - Approval
No biomarker
RCC
axitinib
Sensitive: A1 - Approval
No biomarker
RCC
pazopanib
Sensitive: A1 - Approval
BRCA1 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
BRCA2 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
No biomarker
RCC
aldesleukin
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
HRD
Prostate Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
zoledronic acid
Sensitive: A1 - Approval
PD-L1 overexpression
Urothelial Cancer
tislelizumab
Sensitive: A1 - Approval
No biomarker
RCC
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
toripalimab
Sensitive: A1 - Approval
No biomarker
RCC
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
leuprolide mesylate injectable suspension
Sensitive: A1 - Approval
VHL mutation
RCC
belzutifan
Sensitive: A1 - Approval
No biomarker
Testicular Seminoma
TI-CE
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
TI-CE
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
CaT
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
VC
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
EP
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
GemOx
Sensitive: A2 - Guideline
MSI-H/dMMR
Prostate Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
cetuximab
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
cisplatin
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
5-fluorouracil + mitomycin
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
cisplatin + irinotecan
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
imiquimod
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
TIP
Sensitive: A2 - Guideline
MSI-H/dMMR
Penile Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
BEP
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
EP
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
VIP
Sensitive: A2 - Guideline
No biomarker
Testicular Seminoma
EP
Sensitive: A2 - Guideline
No biomarker
Testicular Seminoma
VeIP
Sensitive: A2 - Guideline
No biomarker
Testicular Seminoma
BEP
Sensitive: A2 - Guideline
No biomarker
Testicular Seminoma
carboplatin
Sensitive: A2 - Guideline
No biomarker
Testicular Seminoma
VIP
Sensitive: A2 - Guideline
TMB-H
Testicular Seminoma
TIP
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
mitoxantrone
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
etoposide IV
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
atezolizumab
Sensitive: A2 - Guideline
No biomarker
RCC
bevacizumab
Sensitive: A2 - Guideline